INVIVYD, INC. Proceeds from License Fees Received
INVIVYD, INC. (IVVD) reported Proceeds from License Fees Received of $200.00 thousand for the 1-month period ending 2023-06-30, per its 10-Q filed 2023-11-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLicenseFeesReceived · last filed 2023-11-09
- 2023-06-30: Proceeds from License Fees Received 1 month $200.00K.
- 2023-02-28: Proceeds from License Fees Received 1 month $400.00K.
| Period end | Proceeds from License Fees Received 1 month |
|---|---|
| 2023-06-30 | $200.00K 10-Q · filed 2023-11-09 |
| 2023-02-28 | $400.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |